Sanofi announced that it will buy pharma company Blueprint Medicines for $129 per share, making the deal worth more than $9 billion. Blueprint specializes in systemic mastocytosis and other ...

A judge has denied City Commissioner Jeremy Matlow's request to have his lawsuit against the Blueprint Intergovernmental Agency board reheard.

Blueprint Medicines soared by 26.09 percent on Monday to close at $127.79 each following news that it is set to be acquired by French pharmaceutical giant Sanofi for $9.1 billion.

2025 NBA Finals: Thunder and Pacers are the modern blueprint of what winning looks like Videos cannot play due to a network issue. Please check your Internet connection and try again.

French drugmaker Sanofi said Monday it has agreed to acquire Blueprint Medicines for up to $9.5 billion, sending shares of the Cambridge, Mass.-based biopharma firm soaring in intraday trading.

France's Sanofi has agreed to buy U.S.-based Blueprint Medicines Corporation for up to $9.5 billion to boost its position in rare immunology diseases, in the biggest deal struck by a European ...

Cambridge-based Blueprint Medicines brings a pipeline of experimental immunology treatments and one medicine already on sale for a rare condition known as systemic mastocytosis.

French pharmaceuticals giant Sanofi has agreed to buy Blueprint Medicines Corp. for at least $9.1 billion as the company aims to expand the company's reach in rare immunological diseases, reported ...

Sanofi SAN-1.02%decrease; red down pointing triangle agreed to buy Blueprint Medicines BPMC 0.04%increase; green up pointing triangle for up to $9.5 billion, the French drugmaker’s biggest move ...

Sanofi and Blueprint Medicines Corporation (Blueprint), a US-based, publicly traded biopharmaceutical company specializing in systemic mastocytosis (SM), a rare immunological disease, and other ...

Sanofi to acquire Blueprint Medicines for up to $9.5B to expand its rare immunological disease portfolio, including an FDA-approved treatment.

Sanofi plans to buy Blueprint Medicines in a deal worth more than $9 billion, expanding its immunology pipeline ...